Gene editing: beyond the hypeGenome editing is an exciting but still nascent field, and companies in the area face as many obstacles Share XGene editing: beyond the hypehttps://pharmaphorum.com/r-d/views-analysis-r-d/genome-editing-sangamo-beyond-the-hype/
Biogen and Sangamo work on Parkinson’s and Alzheimer’s gene therapiesBiogen and Sangamo have begun a collaboration to develop gene regulation therapies for neurological diseases including Parkinson’s and Share XBiogen and Sangamo work on Parkinson’s and Alzheimer’s gene therapieshttps://pharmaphorum.com/news/biogen-and-sangamo-work-on-parkinsons-and-alzheimers-gene-therapies/
Q&A: Sangamo’s Duncan McKay on genomic medicinesWe talk to Duncan McKay, senior vice president and general manager, Europe of Sangamo Therapeutics, about the future Share XQ&A: Sangamo’s Duncan McKay on genomic medicineshttps://pharmaphorum.com/views-analysis-market-access/qa-sangamos-duncan-mckay-on-genomic-medicines/
Kite and Sangamo come together in $3bn cancer gene editing allianceTwo pioneers in the parallel technologies of cell therapy and gene therapy have come together in an ambitious Share XKite and Sangamo come together in $3bn cancer gene editing alliancehttps://pharmaphorum.com/views-analysis-oncology/kite-sangamo-come-together-3bn-cancer-gene-editing-alliance/
No safety concerns so far in Sangamo’s groundbreaking gene-editing trialThe trial of Sangamo’s gene-editing treatment for a rare and debilitating disease has got off to a good Share XNo safety concerns so far in Sangamo’s groundbreaking gene-editing trialhttps://pharmaphorum.com/news/no-safety-concerns-far-sangamos-groundbreaking-gene-editing-trial/
Sangamo and new gene therapy partner Pfizer lifted by FDA fast trackSangamo Therapeutics has been granted a fast track designation from the FDA for SB-525, its gene therapy candidate Share XSangamo and new gene therapy partner Pfizer lifted by FDA fast trackhttps://pharmaphorum.com/news/sangamo-new-gene-therapy-partner-pfizer-lifted-fda-fast-track/
